Twist1 Antibody - #AF4009

(20)   (21)  
製品: Twist1 Antibody
カタログ: AF4009
タンパク質の説明: Rabbit polyclonal antibody to Twist1
アプリケーション: WB IHC IF/ICC
反応性: Human, Mouse, Rat
予測: Pig, Bovine, Chicken, Xenopus
分子量: 29 kd; 21kD(Calculated).
ユニプロット: Q15672
RRID: AB_2835337

類似製品を見る>>

   サイズ 価格 在庫状況
 50ul $250 在庫あり
 100ul $350 在庫あり
 200ul $450 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先
関連ダウンロード
MSDS
説明書
COA
プロトコル
WB Handbook
IHC Protocol
IF/ICC Protocol

製品説明

ソース:
Rabbit
アプリケーション:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse,Rat
予測:
Pig(100%), Bovine(100%), Chicken(100%), Xenopus(100%)
クローナリティ:
Polyclonal
特異性:
Twist1 Antibody detects endogenous levels of total Twist1.
RRID:
AB_2835337
引用形式: Affinity Biosciences Cat# AF4009, RRID:AB_2835337.
コンジュゲート:
Unconjugated.
精製:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ／展開

ACS3; B-HLH DNA binding protein; bHLHa38; BPES2; BPES3; Class A basic helix-loop-helix protein 38; CRS; CRS1; CSO; H-twist; OTTHUMP00000116043; SCS; TWIST; Twist basic helix loop helix transcription factor 1; Twist family bHLH transcription factor 1; Twist homolog 1 (Drosophila); Twist homolog 1; TWIST homolog of drosophila; Twist related protein 1; Twist-related protein 1; TWIST1; TWST1_HUMAN;

免疫原

免疫原:
Uniprot:

Q15672(TWST1_HUMAN) >>Visit HPA database.

遺伝子(ID):
TWIST1(7291)
発現特異性:
Q15672 TWST1_HUMAN:

Subset of mesodermal cells.

タンパク質の説明:
Acts as a transcriptional regulator. Inhibits myogenesis by sequestrating E proteins, inhibiting trans-activation by MEF2, and inhibiting DNA-binding by MYOD1 through physical interaction. This interaction probably involves the basic domains of both proteins. Also represses expression of proinflammatory cytokines such as TNFA and IL1B. Regulates cranial suture patterning and fusion. Activates transcription as a heterodimer with E proteins. Regulates gene expression differentially, depending on dimer composition. Homodimers induce expression of FGFR2 and POSTN while heterodimers repress FGFR2 and POSTN expression and induce THBS1 expression. Heterodimerization is also required for osteoblast differentiation.
タンパク質配列:
MMQDVSSSPVSPADDSLSNSEEEPDRQQPPSGKRGGRKRRSSRRSAGGGAGPGGAAGGGVGGGDEPGSPAQGKRGKKSAGCGGGGGAGGGGGSSSGGGSPQSYEELQTQRVMANVRERQRTQSLNEAFAALRKIIPTLPSDKLSKIQTLKLAARYIDFLYQVLQSDELDSKMASCSYVAHERLSYAFSVWRMEGAWSMSASH

種類予測

種類予測:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Bovine
100
Xenopus
100
Chicken
100
Horse
0
Sheep
0
Dog
0
Zebrafish
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q15672 基板として

Site PTM Type Enzyme
S6 Phosphorylation P28482 (MAPK1)
S18 Phosphorylation P68400 (CSNK2A1)
S20 Phosphorylation P68400 (CSNK2A1)
K38 Ubiquitination
S42 Phosphorylation P31749 (AKT1)
S45 Phosphorylation
S68 Phosphorylation Q15759 (MAPK11) , P45983 (MAPK8) , Q16539 (MAPK14) , P28482 (MAPK1) , P27361 (MAPK3)
K73 Acetylation
S102 Phosphorylation
Y103 Phosphorylation
T121 Phosphorylation
S123 Phosphorylation P31749 (AKT1)
T137 Phosphorylation
K142 Ubiquitination
S144 Phosphorylation
K145 Ubiquitination

研究背景

機能:

Acts as a transcriptional regulator. Inhibits myogenesis by sequestrating E proteins, inhibiting trans-activation by MEF2, and inhibiting DNA-binding by MYOD1 through physical interaction. This interaction probably involves the basic domains of both proteins. Also represses expression of proinflammatory cytokines such as TNFA and IL1B. Regulates cranial suture patterning and fusion. Activates transcription as a heterodimer with E proteins. Regulates gene expression differentially, depending on dimer composition. Homodimers induce expression of FGFR2 and POSTN while heterodimers repress FGFR2 and POSTN expression and induce THBS1 expression. Heterodimerization is also required for osteoblast differentiation. Represses the activity of the circadian transcriptional activator: NPAS2-ARNTL/BMAL1 heterodimer (By similarity).

細胞の位置付け:

Nucleus.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
組織特異性:

Subset of mesodermal cells.

サブユニット構造:

Efficient DNA binding requires dimerization with another bHLH protein. Homodimer or heterodimer with E proteins such as TCF3. ID1 binds preferentially to TCF3 but does not interact efficiently with TWIST1 so ID1 levels control the amount of TCF3 available to dimerize with TWIST1 and thus determine the type of dimer formed (By similarity).

研究領域

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

参考文献

1). Twist1 Regulates Vimentin through Cul2 Circular RNA to Promote EMT in Hepatocellular Carcinoma. CANCER RESEARCH, 2018 (PubMed: 29844124) [IF=11.2]

Application: IHC    Species: mouse    Sample: HCC tumor samples

(E, F) Twist1 and Vimentin expression in the tumor tissues of Twi-L+control, Twi-L+circ-10720, Twi-H+siRNA control and TwiH+si-circ-10720 groups were analyzed via IHC.

Application: WB    Species: human    Sample: HCC cells

Figure 2.| circ-10720 regulated by Twist1 exhibits oncogenic effects in HCC cells.(D) Western blot analysis of Twist1 and Cul2 protein levels in Twist1 overexpression or knockdown cells. Intensity of each band from biological triplicate experiments was quantified by densitometry with the Image J software with GAPDH as a normalizer. *P<0.05, **P<0.01, Student’s t-test.

Application: IHC    Species: human    Sample: tumor

Figure 4. |Intratumoral silencing of circ-10720 blocks the promotive effect of Twist1-mediated on Vimentin expression in a PDTX model of HCC. (E, F) Twist1 and Vimentin expression in the tumor tissues of Twi-L+control, Twi-L+circ-10720, Twi-H+siRNA control and TwiH+si-circ-10720 groups were analyzed via IHC. Each bar represents the mean ± SD for triplicate measurements of four xenografts in each group. **P<0.01, one-way ANOVA.
2). Salidroside improves the hypoxic tumor microenvironment and reverses the drug resistance of platinum drugs via HIF-1α signaling pathway. EBioMedicine, 2018 (PubMed: 30396856) [IF=11.1]

Application: WB    Species: human    Sample: PLC/PRF/5 cells

Fig. 3.|Sal reversed the drug resistance and inhibited HIF-1α signaling pathway. (I) Protein expression level of Twist1, Zeb1 and E-cadherin in PLC/PRF/5 cells treated hypoxia and hypoxia combined with Sal. Error bars represent the standard deviation of experiments performed in triplicate (*P b .05, **P b .01).
3). Prenatal co-exposure to diisodecyl phthalate and ozone contribute to depressive behavior in offspring mice through oxidative stress and TWIST1 participation. The Science of the total environment, 2024 (PubMed: 38608898) [IF=9.8]
4). Hsp90β promotes aggressive vasculogenic mimicry via epithelial-mesenchymal transition in hepatocellular carcinoma. ONCOGENE, 2023 (PubMed: 30087438) [IF=8.0]

Application: WB    Species: human    Sample: SMMC-7721cells

Fig. 4| Hsp90β stabilize Twist1 and promotes its deubiquitination by combining with USP19. a Hsp90β knockdown decreases Twist1 stability. SMMC-7721 cells were transfected with the Hsp90βsiRNA for 24h and then were treated with CHX (100mg/ml) at the indicated time points. b SMMC-7721 cells transfected with Hsp90βsiRNA were treated with 10µM MG132 and followed by immuno-blotting using anti-Twist1 and Hsp90β.

Application: IHC    Species: human    Sample: tumor

Fig. 6 | Hsp90β promotes tumor growth and VM formation relied on Twist1 in vivo and Hsp90 inhibitor depresses the promotion effect.e, f Hsp90β, Twist1, VE-cadherin, E-cadherin, Vimentin,MMP2, and MMP9 expression levels were measured in tumor tissue of the control, Hsp90β overexpression, Hsp90β+ Twist1 siRNA,control shRNA, and Hsp90β knockdown groups by IHC.
5). RETRACTED ARTICLE: Hsp90β promotes aggressive vasculogenic mimicry via epithelial–mesenchymal transition in hepatocellular carcinoma. Oncogene, 2018 (PubMed: 30087438) [IF=8.0]
6). Subtle structural alteration in indisulam switches the molecular mechanisms for the inhibitory effect on the migration of gastric cancer cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2024 (PubMed: 38359488) [IF=7.5]

Application: WB    Species: Human    Sample: AGS and MGC803 cells

Fig. 2. Compounds SR‐3‐65 and WXM‐1‐170 regulated the protein level of EMT biomarkers and transcription factors in AGS and MGC803 cells. (A, B) SR-3–65 and WXM-1–170 altered the protein level of EMT biomarkers. AGS (A) and MGC803 (B) cells were treated with DMSO, indisulam, SR-3–65, or WXM-1–170 (10 µM) for 72 h. Cell lysates were immunoblotted. Mean ± SD (n = 3). One-way ANOVA, Dunnett’s post hoc analysis, *: P < 0.05, **: P < 0.01, ***: P < 0.001, ns: not significant. (C, D) SR-3–65 and WXM-1–170 downregulated the protein level of EMT-related transcription factors. AGS (C) and MGC803 (D) cells were treated with DMSO, indisulam, SR-3–65, or WXM-1–170 (10 µM) for 72 h. Cell lysates were immunoblotted. Mean ± SD (n = 3). One-way ANOVA, Dunnett’s post hoc analysis, *: P < 0.05, **: P < 0.01, ***: P < 0.001, ****: P < 0.0001, ns: not significant.
7). Molecular mechanism of albumin in suppressing invasion and metastasis of hepatocellular carcinoma. LIVER INTERNATIONAL, 2022 (PubMed: 34854209) [IF=6.7]

Application: WB    Species: Human    Sample: HepG2 and Huh7 cells

FIGURE 7 A, Representative images of the western blot results for uPAR, MMP2 and MMP9 in ALB knockdown HepG2 and Huh7 cells; B, Zymography analysis illustrates MMP2 and MMP9 activity in ALB knockdown HepG2 and Huh7 cells; C, Quantitative analysis results and representative images of the western blot results for the EMT‐associated markers, E‐cadherin, N‐cadherin, vimentin, Snail and Twist by western blot in ALB knockdown HepG2 and Huh7 cells; D, Quantification shows a significantly higher uPAR in HCC group with ALB <3.5 g/dL compared to ALB ≥3.5 g/dL (*P < .05); E, Scatterplot showing the correlation between plasma levels of ALB and uPAR. The vertical position represents the expression levels of uPAR (lg pg/mL)
8). Long non‐coding RNA LINC01137 contributes to oral squamous cell carcinoma development and is negatively regulated by miR-22-3p. CELLULAR ONCOLOGY, 2021 (PubMed: 33797737) [IF=6.6]

Application: WB    Species: Human    Sample: HSC3 and Tca8113 cells

Fig. 3 LINC01137 downregulation inhibits OSCC cell migration and invasion. a Transwell chambers were used to detect the effect of LINC01137 knockdown on the migration of HSC3 and Tca8113 cells. n = 10 fields, **p < 0.01. b Transwell chambers precoated with Matrigel were used to detect the effect of LINC01137 knockdown on the invasion of HSC3 and Tca8113 cells. n = 10 fields, **p < 0.01. c Western blotting was performed to detect the expression of EMT related proteins (Vimentin, Snail, Twist, MMP-2 and MMP-9) after LINC01137 knockdown in HSC3 and Tca8113 cells. n = 3, *p < 0.05
9). Phenylpropenol ester and sesquiterpenoids with antimetastatic activities from the whole plants of Chloranthus japonicus. Arabian Journal of Chemistry, 2022 [IF=6.0]
10). Cytoplasmic p27 is a novel prognostic biomarker and oncogenic protein for nasopharyngeal carcinoma. Artificial Cells Nanomedicine and Biotechnology, 2020 (PubMed: 31884829) [IF=5.8]
もっと読みます

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.